Navigation Links
Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight

SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of Andrew J. McKnight, Ph.D. as Senior Director, Target Biology.  Dr. McKnight comes to AnaptysBio with extensive experience in the design and development of novel therapeutic antibodies across a variety of therapeutic areas.  Working together with David J. King, Ph.D., AnaptysBio's chief scientific officer, Dr. McKnight will be leading the advancement of AnaptysBio's current and future internal pipeline programs. 


AnaptysBio's primary objective is the advancement of novel therapeutic antibody programs generated using the Company's proprietary SHM-XEL platform.  As the first company to replicate somatic hypermutation (SHM) in vitro for antibody discovery, AnaptysBio's SHM-XEL platform is uniquely positioned to generate therapeutic antibodies with unique functionality.  The Company is currently pursuing differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio's internal programs are independent of the Company's partnerships with Merck, Roche, Novartis, Celgene, Gilead and DARPA. 

Dr. McKnight comes to AnaptysBio most recently from Pfizer's Biotherapeutics group, where he directed numerous internal and partnered antibody development projects.  Prior to Pfizer, Dr. McKnight led antibody projects at UCB-Celltech. Dr. McKnight received his doctorate from University of Oxford and was a postdoctoral fellow at Harvard Medical School. 

"We are delighted to add Andrew's target biology experience to AnaptysBio's research and development team," said Hamza Suria, AnaptysBio's president and chief executive officer. "The unique strengths of our SHM-XEL platform provide AnaptysBio with distinct advantages in the design and discovery of novel therapeutic antibodies."

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies.  AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, functionality, cross-reactivity and epitope diversity.   AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene and Gilead.  Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Healthcare Ventures, and Novo A/S. For more information, visit

SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asthmapolis Expands Dignity Health Study to Include Mercy Medical Group Patients
2. Hospira Expands Board of Directors With Election of Dennis M. Fenton
3. The MED Group Expands MED Suppliers Network to add Ventilator Program
4. Integrity Life Sciences Expands Orthotic Options for Domestic and International Customers
5. Practice Fusion Expands Executive Team with Addition of General Counsel and Associate VP of Corporate Development
6. OceanGate Inc. Expands Board of Directors with Two Key Appointments
7. ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment
8. Acquisition of Navigenics Expands Life Technologies Capabilities in Diagnostics
9. Echo Therapeutics Expands License Agreement with Ferndale Pharma
10. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
11. Dr. Jills Foot Pads Secures GSA Schedule and Expands to Service VA and Federal Agencies
Post Your Comments:
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
Breaking Medicine News(10 mins):